RxDoctor Payments Data

Timothy Janz, MD

Internal Medicine · Punta Gorda, FLNPI 1659342004

Payments from drug & device makers

$2,971in general payments, 2019–2025

Across 65 payments — averaging $45.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$520
  • Novo Nordisk$439
  • Boston Scientific$327
  • Pfizer$291
  • Lilly USA, LLC$251
  • Abbott$221
  • plus $921 from 11 others

What the payments were for

  • Food & beverage$2,81695%
  • Education$1555%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,971 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$175,306
Medicare patients
303
Services billed
3,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$114,126
TrulicityDulaglutide52$70,311
Repatha SureclickEvolocumab56$66,875
OzempicSemaglutide44$48,656
MounjaroTirzepatide41$44,760
XareltoRivaroxaban23$30,985
EntrestoSacubitril/Valsartan28$30,877
JardianceEmpagliflozin27$27,952
MyrbetriqMirabegron15$16,378
Testosterone45$7,947
Breo ElliptaFluticasone/Vilanterol14$6,905
Levothyroxine Sodium416$5,551
Rosuvastatin Calcium318$4,866
Fenofibrate28$4,696
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$291$116,985138 claims
Lilly USA, LLCTrulicity, Mounjaro$251$115,07193 claims
Novo NordiskOzempic$439$48,65644 claims
NovartisEntresto$30$30,87728 claims
Boehringer IngelheimJardiance$125$27,95227 claims
Astellas Pharma US IncMyrbetriq$155$16,37815 claims
AbbVieSynthroid$23$3,43284 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Punta Gorda

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →